SCHEMBL1644904

SCHEMBL1644904

C1=Cc2ccc3cccnc3c2NC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
KDM4E B2RXH2 3/20 0.48
MAPT P10636 3/20 0.48
TSHR P16473 3/20 0.48
CCR1 P32246 3/20 0.48
CCR5 P51681 3/20 0.48
CCR8 P51685 3/20 0.48
ALOX15 P16050 2/20 0.48
HTT P42858 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
MMP2 P08253 2/20 0.48
GMNN O75496 1/20 0.48
TP53 P04637 1/20 0.48
HSP90AA1 P07900 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MMP9 P14780 1/20 0.48
NFKB1 P19838 1/20 0.48
MMP8 P22894 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL28008200 0.91 LMNA (0.41) LMNAKDM4EMAPTTSHRCCR1
SCHEMBL30619089 0.86 LMNA (0.44) LMNAKDM4EMAPTTSHRCCR1
SCHEMBL26901615 0.81 CCR1 (0.37) LMNAKDM4EMAPTTSHRCCR1
SCHEMBL16976515 0.81 BRD4 (0.37) LMNAKDM4EMAPTTSHRCCR1
SCHEMBL12446438 0.77 SLC40A1 (0.35) SLC40A1
SCHEMBL31260254 0.76 MAPK14 (0.31)
SCHEMBL23954295 0.75 ABL1 (0.34) LMNAKDM4EMAPTTSHRCCR1
SCHEMBL2630611 0.75 CCR1 (0.50) LMNAKDM4EMAPTTSHRCCR1
SCHEMBL17422686 0.74 LMNA (0.37) LMNAMAPTTSHRSMN1; SMN2TDP1
SCHEMBL29639994 0.74 ALDH1A1 (0.39) LMNAKDM4EMAPTTSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240155939-A1 HETEROCYCLIC AROMATIC AMINE COMPOUND AND ELECTROLUMINESCENCE USING THE SAME WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) 2024-05-09 US claimed
US-8530593-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-10 US claimed
CN-102552261-A Methods of increasing endogenous erythropoietin EPO FIBROGEN INC 2012-07-11 CN claimed
WO-2011056432-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO claimed
US-20110098431-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US claimed
US-20250255096-A1 LIGHT EMITTING DEVICE AND LIGHT EMITTING DISPLAY DEVICE LG DISPLAY CO., LTD. (KR) 2025-08-07 US disclosed
EP-3246347-B1 CONJUGATED POLYMER CONTAINING ETHYNYL CROSSLINKING GROUP, MIXTURE, COMPOSITION, ORGANIC ELECTRONIC DEVICE CONTAINING THE SAME AND APPLICATION THEREOF GUANGZHOU CHINARAY OPTOELECTRONIC MAT LTD (CN) 2025-04-23 EP disclosed
CN-111138463-B Organic electroluminescent device and polycyclic compound for organic electroluminescent device 三星显示有限公司 2025-02-25 CN disclosed
CN-118895063-A Ink composition and display device 三星显示有限公司 2024-11-05 CN disclosed
CN-118580208-A Light-emitting element and amine compound for light-emitting element 三星显示有限公司 2024-09-03 CN disclosed
CN-118290453-A Light-emitting element and condensed polycyclic compound for light-emitting element 三星显示有限公司 2024-07-05 CN disclosed
CN-118270845-A Lithium manganate positive electrode material, preparation method thereof, lithium extraction adsorbent, pole piece and battery 广东邦普循环科技有限公司 2024-07-02 CN disclosed
EP-0280470-B1 METHOD OF PURIFYING RECOMBINANT PRES-1/S-2/S HEPATITIS B ANTIGEN FROM YEAST MERCK & CO. INC. (US) 1993-07-07 EP disclosed
US-5026828-A Releasing undesired proteins, followed by releasing hepatitis B; diafiltration MERCK & CO., INC. (US) 1991-06-25 US disclosed
US-5011915-A Centrifuging yeast membrane extract, then diafiltation in guanidine hydrochloride solution, solubilizing with denaturing agent and reducing agent MERCK & CO., INC. (US) 1991-04-30 US disclosed
EP-0340837-A1 Recombinant GAG precursor of HIV, product, process, and use as aids vaccine MERCK & CO. INC. (US) 1989-11-08 EP disclosed
EP-0315242-A2 Process for purifying recombinant hepatitis antigens MERCK & CO. INC. (US) 1989-05-10 EP disclosed
EP-0314240-A2 Process for purifying recombinant hepatitis antigens MERCK & CO. INC. (US) 1989-05-03 EP disclosed
EP-0312164-A1 Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells MERCK & CO. INC. (US) 1989-04-19 EP disclosed
EP-0280470-A1 Method of purifying recombinant pres-1/S-2/S hepatitis B antigen from yeast MERCK & CO. INC. (US) 1988-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098431-A1 Catalyst Compounds and Use Thereof PAM, AAAS, PAOX LMNA 2933/4885KDM4E 3249/4885MAPT 118/4885
US-20240155939-A1 HETEROCYCLIC AROMATIC AMINE COMPOUND AND ELECTROLUMINESCENCE USING THE SAME CCNL2, CHRM1, AHR LMNA 365/4885KDM4E 2787/4885MAPT 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.